Intellectual Property
Nov. 8, 2022
US Supreme Court to review Patent Act section for 2nd time in history
If the high court affirms the Federal Circuit Court’s ruling against Amgen Inc. of Thousand Oaks, the justices’ decision could shake up drug patent requirements, meaning companies would need to adjust to a new patent acquisition process.
US Supreme Court to review Patent Act section for 2nd time in history
The U.S. Supreme Court agreed to consider a patent infringement case appeal by a California company that will be the second instance in history Section 112 of the Patent Act of 1952 has been reviewed.
If the high court affirms the Federal Circuit Court’s ruling, the justices’ decision could shake up drug patent requirements, meaning companies...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In